ArticleCancer immunology, immunotherapy : CII2026
Integrated immunophenotypic and ProMisE molecular profiling as predictors of immune checkpoint inhibitor response in recurrent endometrial cancer.
Komei Katayama et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.